AstraZeneca has admitted for the first time in court documents that its covid vaccine can cause side effects such as thrombosis in “very rare cases.” The pharmaceutical giant has expressed this in a text presented to the High Court of the United Kingdom in February, as the British newspaper now explains. The Telegraph.
This statement is produced within the framework of a judicial process after the filing a class action lawsuit against the company for considering that its vaccinedeveloped in collaboration with the University of Oxford, It has caused death and serious injury in dozens of cases. Lawyers maintain that this jab produced a side effect that has caused devastating consequences for a small number of families.
The first case was filed last year by Jamie Scott, father of two, who was left with a permanent brain injury after developing a blood clot and hemorrhage in the brain which prevented him from working after receiving the vaccine in April 2021. In fact, the hospital called his wife three times to tell her that her husband was going to die.
In total, they have been presented 51 cases before the British High Courtand the victims and their families are seeking damages worth an estimated up to £100 million.
“Can cause TTS”
Although in a response letter sent In May 2023, AstraZeneca told Scott’s lawyers that “we do not accept that TTS is caused by the vaccine at the generic level.” In the new document presented in February before the high court They accepted that their Covid vaccine “may, in very rare cases, cause TTS.”
Specifically, in the legal document presented, AstraZeneca noted: “It is recognized that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is unknown.”
IT MAY INTEREST YOU
The reactions of anti-vaccines when they are hospitalized: “Can’t I take it now?”
Fran Sánchez Becerril
TTS is the English acronym for thrombosis syndrome with thrombocytopeniawhich causes people to have blood clots and a low blood platelet count.
This statement that could pave the way for the payment of compensation that are claimed.
Europe was already monitoring this assumption
The scientists identified for the first time a link between the vaccine and a new disease called immune thrombocytopenia and thrombosis Vaccine-Induced Infections (VITT) as early as March 2021, shortly after the Covid-19 vaccine rollout began. Although lawyers for the British plaintiffs argue that VITT is a subset of TTS, AstraZeneca does not appear to recognize the term.
The European Pharmacovigilance Risk Assessment Committee (PRAC) examined this relationship when it was discovered. In April 2021 issued a document following evaluation of available data on reported cases of thrombosis following vaccination with Vaxzevria (AstraZeneca COVID-19 vaccine) which concluded:
- After the administration of Vaxzevria may occur, very rarely, thrombosis in combination with thrombopeniasuch as cerebral venous sinus thrombosis (CSVT), in the abdomen (splanchnic vein thrombosis) and arterial thrombosis.
- The identified cases have occurred mostly in women under 60 years of age in the two weeks after administration of the vaccine. No specific risk factors for its appearance have been identified.
- It is recommended to health professionals and citizens monitor for possible signs and symptoms of thrombosis and thrombocytopenia for early diagnosis and treatment.
AstraZeneca has admitted for the first time in court documents that its covid vaccine can cause side effects such as thrombosis in “very rare cases.” The pharmaceutical giant has expressed this in a text presented to the High Court of the United Kingdom in February, as the British newspaper now explains. The Telegraph.
